Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein))

Written2009-05Yasunobu Matsuda
Department of Medical Technology, Niigata University Graduate School of Health Sciences, Asahimachi-dori 2-746, Niigata 9518518, Japan

(Note : for Links provided by Atlas : click)

Identity

Alias_namesBGP
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Alias_symbol (synonym)BGP1
CD66a
Other aliasBGPI
HGNC (Hugo) CEACAM1
LocusID (NCBI) 634
Atlas_Id 40044
Location 19q13.2  [Link to chromosome band 19q13]
Location_base_pair Starts at 42507306 and ends at 42528509 bp from pter ( according to hg19-Feb_2009)  [Mapping CEACAM1.png]
Local_order centromere - CGM7(CEACAM4) - CGM2(CEACAM7) - CEA(CEACAM5) - NCA(CEACAM6) - CGM1(CEACAM3) - CEACAM1 - CGM9(CEACAMP2) - CGM6(CEACAM8) - CGM8(CEACAMP1) - telomere.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

Note The locus is complex, and it produces several proteins via alternative splicing.
 
  Genomic structure of human CEACAM1. Open and closed boxes indicate untranslated regions and coding regions (exons) of CEACAM1 gene, respectively. The ATG initiation codon is located in the first exon, and the TGA termination codon is located in exon 9. N, A1, B1 and A2; Ig domains, TM; transmembrane domain, C; cytoplasmic domain.
Description The gene is composed of 9 exons spanning in a region of 23,140 bp (Localized from 47,724,479 to 47,703,298 from pter).
Transcription Human CEACAM1 consists of 9 exons that can be alternatively spliced to generate 11 different isoforms. The gene contains 19 different introns, and the sequence is supported by 286 sequences from 262 cDNA clones. The transcripts differ by truncation of the N-terminus, truncation of the C-terminus, presence or absence of a cassette exon, common exons with different boundaries. Among various types of isoforms, the full-length nature of two alternative transcripts (NM_001024912.1, NM_001712.3) has been determined.
Pseudogene Eleven pseudogenes of the CEA cell adhesion molecule subgroup are found in the cluster of the two subgroups of the CEA family (the CEA cell adhesion molecules and the pregnancy-specific glycoproteins which locate within a 1.2 Mb cluster on the long arm of chromosome 19).

Protein

 
  In human, 11 different CEACAM1 splice variants have been reported. The domain structure of each protein isoform is illustrated as open box. N; N-terminal immunoglobulin variable-region-like (IgV-like) domain, A or B; subsets of constant-region-type-2-like (IgC2-like) domains, TM; transmembrane domain, C; cytoplasmic domain. Nomenclature number after CEACAM1 indicates the number of extracellular immunoglobulin-like domains, whereas the letter that follows this indicates the presence of either a long (L) or a short (S) cytoplasmic tail, a unique termini (C), or an Alu family repeat sequence present within the open reading frame (A). For example, CEACAM1 with four extracellular immunoglobulin-like domains and with a long cytoplasmic domain is called as CEACAM1-4L. The most common isoforms expressed by human immune cells are CEACAM1-4L, CEACAM1-3L, CEACAM1-4S and CEACAM1-3S.
Description CEACAM1 is a single-pass type-1 glycoprotein which belongs within the Ig gene superfamily. It contains a 34 amino acid (aa) leader sequence, an extracellular domain which contains a N-terminal IgV-like domain and three of IgC2-like domains (382 aa), a transmembrane domain (43 aa), a cytoplasmic domain (67 aa) and two of the potential tyrosine phosphorylation sites. CEACAM1 is heavily N-glycosylated with more than 60% of the mass contributed by N-linked glycans.
Localisation CEACAM1 isoforms with transmembrane domain are mostly cell-membrane anchored, whereas those without transmembrane domain are secreted. They are mostly expressed in cells of epithelial and endothelial, lymphoid and myeloid cells.
Function CEACAM1 is capable of homophilic with CEACAM1 or heterophilic adhesion with CEA and CEACAM6. Isoforms of CEACAM1 with a long cytoplasmic domain generally transmit inhibitory signals, whereas isoforms with a short cytoplasmic domain indicate a regulated interaction with the cytoskeleton. CEACAM1 has been implicated in various types of intercellular-adhesion and intracellular-signaling of cell survival, differentiation and growth in both normal and cancer cells as follows:
(1) CEACAM1 inhibits proliferation of both epithelial cells and T lymphocytes by a contact-mediated mechanism. In monocytes, CEACAM1 regulates phosphatidylinositol 3-kinase (PI3K) and Akt-dependent survival signal and inhibits apoptosis.
(2) CEACAM1 induces apoptosis of mature colonocytes and mammary epithelial cells, which is in part of a morphogenetic process in the formation of glandular lumen.
(3) CEACAM1 has been demonstrated to stimulate cellular migration of blood vessel endothelial cells.
(4) In granulocytes, CEACAM1 mediates the binding to endothelial E-selectin.
(5) The involvement of CEACAM1 in carcinogenesis is complex. In some types of cancer cells such as colon cancer and hepatoma loss or reduced expression of CEACAM1 is frequently observed, thereby it has been regarded as a tumor suppressor. However, in other types, for example, thyroid cancer and gastric cancer, CEACAM1 is up-regulated.
(6) CEACAM1 exerts angiogenic properties and is a major effecter of VEGF in the early vascular formation. Since CEACAM1 is mainly expressed in tumor microvessels but not in large blood vessels, it may be a target for the therapy of tumor angiogenesis.
(7) Neisseria gonorrhea triggers expression of CEACAM1 on primary endothelial cells by activating the immediate early response transcription factor NF-kappaB. Neisseria gonorrhoeae colony opacity-associated (Opa) proteins bind to human CEACAM on host cells including T lymphocytes, and Opa binding to CEACAM1 suppresses the activation of CD4+ T cells in response to a variety of stimuli.
(8) CEACAM1 regulates insulin clearance in the liver.
Homology CEACAM1 is the human homolog of a cell adhesion molecule (CAM) of the rat designated Cell-CAM.
Rattus norvegicus: 70.74 (n), 56.12(a) (Percentage Identity).
Mus musculus: 72.3 (n), 58.25 (a).

Implicated in

Note
  
Entity Colon cancer
Note CEACAM1 mRNA was demonstrated to be down-regulated to < or = 0.4 in 80% of 21 colorectal carcinoma tissue specimens as compared with the respective adjacent normal mucosa (Neumaier et al., 1993). CEACAM1 was reported to be associated with pp60c-src, suggesting that down-regulation of CEACAM1 in about 80% of colorectal carcinomas may contribute to a dysfunction of pp60c-src in colorectal cancer (Brummer et al., 1995).
  
  
Entity Hepatocellular carcinoma
Note CEACAM1 was reported to be diffusely expressed in 113 of 139 hepatomas. Loss of CEACAM1 expression was closely associated with large tumor size, multiplicity of the tumor, portal vein invasion, and satellite nodules and affected survival adversely, according to univariate (P < 0.0001) and multivariate analyses (relative risk, 5.737; P < 0.001) (Cruz et al., 2005). In rat hepatoma cells 1682A, restoration of CEACAM1-4L expression was demonstrated to completely suppress the tumor formation (Laurie et al., 2005). In human hepatoma cell lines (HLF, PLC/PRF/5, HepG2 and KYN-2), CEACAM1 protein was demonstrated to only express in HepG2, which shows a strong property for enhanced anchorage-independent growth. It was reported that CEACAM1 acts as a tumor suppressor when the cells are cultured in anchorage-dependent growth conditions. In contrast, in anchorage-independent growth conditions, CEACAM1 augments cell proliferation by potentiating the cell-cell attachment (Hokari et al., 2007).
  
  
Entity Breast cancer
Note CEACAM1 is down-regulated in around 30% of breast cancers. CEACAM1 is reported to suppress the tumorigenicity of breast cancer cells via its cytoplasmic domain but not the extracellular domain (Luo et al., 1997). CEACAM1 is demonstrated to be consistently expressed in normal tissue and benign lesions of mammary gland, whereas it disappears with the development of the malignant phenotype in both noninvasive and invasive carcinoma (Riethdorf et al., 1997). CEACAM1 is reported to be expressed at high levels in cribiform ductal carcinoma in situ (DCIS). Although most invasive ductal carcinomas express CEACAM1 weakly, tumours with minimal lumena formation show cytoplasmic CEACAM1 expression (Kirshner et al., 2004).
  
  
Entity Prostate cancer
Note CEACAM1 is reported to be regulated by androgen and might act as a growth repressor during differentiation of the prostatic epithelium. Forced expression of CEACAM1 results in the significantly lower growth rates of human prostatic cancer cell line PC-3 (Hsieh et al., 1995).
  
  
Entity Bladder cancer
Note CEACAM1 is expressed in umbrella cells of bladder urothelium, but is down-regulated in superficial bladder cancer. CEACAM1 silencing in bladder cancer cell lines 486p and RT4 using the small interfering RNA technique leads to a significant up-regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D, suggesting that the epithelial down-regulation of CEACAM1 induces angiogenesis via increased expression of VEGF-C and VEGF-D (Oliveira-Ferrer et al., 2004).
  
  
Entity Melanoma
Note A total of 28 of 40 patients with CEACAM1-positive primary melanomas developed metastatic disease, compared with only six of 60 patients with CEACAM1-negative melanomas. the strongest CEACAM1 expression was observed at the invading front. Kaplan-Meier analysis revealed a highly significant association between CEACAM1 expression and metastasis (P <.0001) (Thies et al., 2002).
  
  
Entity Renal cell carcinoma
Note In normal kidney, CEACAM1 was found in epithelial cells of proximal tubules and in endothelial cells. In contrast, tumour cells of 30 clear cell, three chromophobic, and two chromophilic RCCs were completely devoid of CEACAM1. Renal adenomas also lacked CEACAM1 expression. Similarly, RCC cell lines CaKi1, CaKi2, A498, and RCC26 exhibited no or low-level CEACAM1 expression. However, CEACAM1 expression was transiently induced in A498 cells upon contact with allogeneic CD8+ T cells, mediated at least in part by interferon-gamma. Furthermore, the majority of tumour-infiltrating T and NK cells expressed CEACAM1 upon stimulation. Thus, transient expression of the tumour suppressor CEACAM1 by tumour cells and subsequent homophilic interaction with CEACAM1 on tumour-infiltrating lymphocytes could represent a novel immune escape mechanism in RCC (Kammerer et al., 2004).
  

To be noted

The role of CEACAM1 in cancer may be different among different types of cancer. CEACAM1 is down-regulated in colon carcinomas, hepatocellular carcinomas, a proportion of breast cancers. In contrast, in prostate cancer and bladder cancer, CEACAM1 is down-regulated in the cancer cells, whereas overexpressed in blood microvessels and lymphatic capillaries and in the vicinity of the tumor. In thyroid cancer, gastric cancer and metastasing malignant melanomas, CEACAM1 is increased.

Bibliography

CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.
Abou-Rjaily GA, Lee SJ, May D, Al-Share QY, Deangelis AM, Ruch RJ, Neumaier M, Kalthoff H, Lin SH, Najjar SM.
J Clin Invest. 2004 Oct;114(7):944-52.
PMID 15467833
 
Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas.
Brummer J, Neumaier M, Gopfert C, Wagener C.
Oncogene. 1995 Oct 19;11(8):1649-55.
PMID 7478590
 
Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma.
Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K.
Cancer. 2005 Jul 15;104(2):354-60.
PMID 15952183
 
CEACAM1: contact-dependent control of immunity.
Gray-Owen SD, Blumberg RS.
Nat Rev Immunol. 2006 Jun;6(6):433-46. (REVIEW)
PMID 16724098
 
Tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 potentates the anchorage-independent growth of human hepatoma HepG2 cells.
Hokari M, Matsuda Y, Wakai T, Shirai Y, Sato M, Tsuchiya A, Takamura M, Yamagiwa S, Suzuki K, Ohkoshi S, Ichida T, Kawachi H, Aoyagi Y.
Life Sci. 2007 Jul 4;81(4):336-45. Epub 2007 Jun 16.
PMID 17612570
 
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo.
Horst AK, Ito WD, Dabelstein J, Schumacher U, Sander H, Turbide C, Brummer J, Meinertz T, Beauchemin N, Wagener C.
J Clin Invest. 2006 Jun;116(6):1596-605. Epub 2006 May 4.
PMID 16680193
 
Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.
Hsieh JT, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH.
Cancer Res. 1995 Jan 1;55(1):190-7.
PMID 7805032
 
The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.
Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W.
J Pathol. 2004 Nov;204(3):258-67.
PMID 15476270
 
Cell-cell adhesion molecule CEACAM1 is expressed in normal breast and milk and associates with beta1 integrin in a 3D model of morphogenesis.
Kirshner J, Hardy J, Wilczynski S, Shively JE.
J Mol Histol. 2004 Mar;35(3):287-99. (REVIEW)
PMID 15339048
 
Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters.
Koelma IA, Nap M, Huitema S, Krom RA, Houthoff HJ.
Arch Pathol Lab Med. 1986 Nov;110(11):1035-40.
PMID 2430547
 
CEACAMs: their role in physiology and pathophysiology.
Kuespert K, Pils S, Hauck CR.
Curr Opin Cell Biol. 2006 Oct;18(5):565-71. Epub 2006 Aug 17. (REVIEW)
PMID 16919437
 
Carcinoembryonic antigen-related cell adhesion molecule 1a-4L suppression of rat hepatocellular carcinomas.
Laurie NA, Comegys MM, Carreiro MP, Brown JF, Flanagan DL, Brilliant KE, Hixson DC.
Cancer Res. 2005 Dec 1;65(23):11010-7.
PMID 16322250
 
Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains.
Luo W, Wood CG, Earley K, Hung MC, Lin SH.
Oncogene. 1997 Apr 10;14(14):1697-704.
PMID 9135071
 
Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas.
Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C.
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10744-8.
PMID 7504281
 
Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer.
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergun S.
Cancer Res. 2004 Dec 15;64(24):8932-8.
PMID 15604255
 
CEACAM1 regulates insulin clearance in liver.
Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM.
Nat Genet. 2002 Mar;30(3):270-6. Epub 2002 Feb 19.
PMID 11850617
 
Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland.
Riethdorf L, Lisboa BW, Henkel U, Naumann M, Wagener C, Loning T.
J Histochem Cytochem. 1997 Jul;45(7):957-63.
PMID 9212821
 
CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells.
Slevogt H, Zabel S, Opitz B, Hocke A, Eitel J, N'guessan PD, Lucka L, Riesbeck K, Zimmermann W, Zweigner J, Temmesfeld-Wollbrueck B, Suttorp N, Singer BB.
Nat Immunol. 2008 Nov;9(11):1270-8. Epub 2008 Oct 5.
PMID 18836450
 
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U.
J Clin Oncol. 2002 May 15;20(10):2530-6.
PMID 12011132
 
Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1.
Wagener C, Ergun S.
Exp Cell Res. 2000 Nov 25;261(1):19-24. (REVIEW)
PMID 11082271
 

Citation

This paper should be referenced as such :
Matsuda, Y
CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein))
Atlas Genet Cytogenet Oncol Haematol. 2010;14(4):361-364.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/CEACAM1ID40044ch19q13.html


External links

Nomenclature
HGNC (Hugo)CEACAM1   1814
Cards
AtlasCEACAM1ID40044ch19q13
Entrez_Gene (NCBI)CEACAM1  634  carcinoembryonic antigen related cell adhesion molecule 1
AliasesBGP; BGP1; BGPI
GeneCards (Weizmann)CEACAM1
Ensembl hg19 (Hinxton)ENSG00000079385 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000079385 [Gene_View]  chr19:42507306-42528509 [Contig_View]  CEACAM1 [Vega]
ICGC DataPortalENSG00000079385
TCGA cBioPortalCEACAM1
AceView (NCBI)CEACAM1
Genatlas (Paris)CEACAM1
WikiGenes634
SOURCE (Princeton)CEACAM1
Genetics Home Reference (NIH)CEACAM1
Genomic and cartography
GoldenPath hg38 (UCSC)CEACAM1  -     chr19:42507306-42528509 -  19q13.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)CEACAM1  -     19q13.2   [Description]    (hg19-Feb_2009)
EnsemblCEACAM1 - 19q13.2 [CytoView hg19]  CEACAM1 - 19q13.2 [CytoView hg38]
Mapping of homologs : NCBICEACAM1 [Mapview hg19]  CEACAM1 [Mapview hg38]
OMIM109770   
Gene and transcription
Genbank (Entrez)AK314211 AL833584 AY766113 BC014473 BC024164
RefSeq transcript (Entrez)NM_001024912 NM_001184813 NM_001184815 NM_001184816 NM_001205344 NM_001712
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)CEACAM1
Cluster EST : UnigeneHs.512682 [ NCBI ]
CGAP (NCI)Hs.512682
Alternative Splicing GalleryENSG00000079385
Gene ExpressionCEACAM1 [ NCBI-GEO ]   CEACAM1 [ EBI - ARRAY_EXPRESS ]   CEACAM1 [ SEEK ]   CEACAM1 [ MEM ]
Gene Expression Viewer (FireBrowse)CEACAM1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)634
GTEX Portal (Tissue expression)CEACAM1
Human Protein AtlasENSG00000079385-CEACAM1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP13688   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP13688  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP13688
Splice isoforms : SwissVarP13688
PhosPhoSitePlusP13688
Domaine pattern : Prosite (Expaxy)IG_LIKE (PS50835)   
Domains : Interpro (EBI)Ig-like_dom    Ig-like_fold    Ig_sub    Ig_sub2    Ig_V-set    Immunoglobulin   
Domain families : Pfam (Sanger)ig (PF00047)    Ig_2 (PF13895)    V-set (PF07686)   
Domain families : Pfam (NCBI)pfam00047    pfam13895    pfam07686   
Domain families : Smart (EMBL)IG (SM00409)  IGc2 (SM00408)  
Conserved Domain (NCBI)CEACAM1
DMDM Disease mutations634
Blocks (Seattle)CEACAM1
PDB (SRS)2GK2    4QXW    4WHD    5DZL   
PDB (PDBSum)2GK2    4QXW    4WHD    5DZL   
PDB (IMB)2GK2    4QXW    4WHD    5DZL   
PDB (RSDB)2GK2    4QXW    4WHD    5DZL   
Structural Biology KnowledgeBase2GK2    4QXW    4WHD    5DZL   
SCOP (Structural Classification of Proteins)2GK2    4QXW    4WHD    5DZL   
CATH (Classification of proteins structures)2GK2    4QXW    4WHD    5DZL   
SuperfamilyP13688
Human Protein Atlas [tissue]ENSG00000079385-CEACAM1 [tissue]
Peptide AtlasP13688
HPRD00191
IPIIPI00009938   IPI00641900   IPI00879975   IPI00935840   IPI00328130   IPI00216039   IPI00018920   IPI00437847   IPI00018936   IPI00644390   IPI00012676   IPI00385428   IPI00981799   IPI01011112   
Protein Interaction databases
DIP (DOE-UCLA)P13688
IntAct (EBI)P13688
FunCoupENSG00000079385
BioGRIDCEACAM1
STRING (EMBL)CEACAM1
ZODIACCEACAM1
Ontologies - Pathways
QuickGOP13688
Ontology : AmiGOangiogenesis  regulation of cell growth  blood vessel development  negative regulation of T cell mediated cytotoxicity  negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target  molecular_function  actin binding  protein binding  plasma membrane  plasma membrane  integral component of plasma membrane  cell-cell junction  adherens junction  negative regulation of protein kinase activity  cell adhesion  homophilic cell adhesion via plasma membrane adhesion molecules  homophilic cell adhesion via plasma membrane adhesion molecules  integrin-mediated signaling pathway  basal plasma membrane  cell surface  cell surface  regulation of endothelial cell migration  regulation of phosphatidylinositol 3-kinase signaling  bile acid transmembrane transporter activity  bile acid and bile salt transport  membrane  integral component of membrane  apical plasma membrane  lateral plasma membrane  cell migration  kinase binding  protein phosphatase binding  cell junction  cell junction  regulation of cell migration  transport vesicle membrane  negative regulation of granulocyte differentiation  filamin binding  microvillus membrane  negative regulation of interleukin-1 production  cellular response to insulin stimulus  specific granule membrane  common myeloid progenitor cell proliferation  insulin receptor internalization  granulocyte colony-stimulating factor signaling pathway  regulation of epidermal growth factor receptor signaling pathway  T cell receptor complex  protein homodimerization activity  protein homodimerization activity  negative regulation of vascular permeability  neutrophil degranulation  negative regulation of cytotoxic T cell degranulation  wound healing, spreading of cells  regulation of endothelial cell differentiation  negative regulation of fatty acid biosynthetic process  protein dimerization activity  negative regulation of T cell receptor signaling pathway  leukocyte migration  negative regulation of lipid biosynthetic process  regulation of blood vessel remodeling  extracellular exosome  regulation of ERK1 and ERK2 cascade  tertiary granule membrane  negative regulation of platelet aggregation  cell-cell adhesion via plasma-membrane adhesion molecules  insulin catabolic process  regulation of homophilic cell adhesion  regulation of sprouting angiogenesis  protein tyrosine kinase binding  negative regulation of hepatocyte proliferation  positive regulation of vasculogenesis  
Ontology : EGO-EBIangiogenesis  regulation of cell growth  blood vessel development  negative regulation of T cell mediated cytotoxicity  negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target  molecular_function  actin binding  protein binding  plasma membrane  plasma membrane  integral component of plasma membrane  cell-cell junction  adherens junction  negative regulation of protein kinase activity  cell adhesion  homophilic cell adhesion via plasma membrane adhesion molecules  homophilic cell adhesion via plasma membrane adhesion molecules  integrin-mediated signaling pathway  basal plasma membrane  cell surface  cell surface  regulation of endothelial cell migration  regulation of phosphatidylinositol 3-kinase signaling  bile acid transmembrane transporter activity  bile acid and bile salt transport  membrane  integral component of membrane  apical plasma membrane  lateral plasma membrane  cell migration  kinase binding  protein phosphatase binding  cell junction  cell junction  regulation of cell migration  transport vesicle membrane  negative regulation of granulocyte differentiation  filamin binding  microvillus membrane  negative regulation of interleukin-1 production  cellular response to insulin stimulus  specific granule membrane  common myeloid progenitor cell proliferation  insulin receptor internalization  granulocyte colony-stimulating factor signaling pathway  regulation of epidermal growth factor receptor signaling pathway  T cell receptor complex  protein homodimerization activity  protein homodimerization activity  negative regulation of vascular permeability  neutrophil degranulation  negative regulation of cytotoxic T cell degranulation  wound healing, spreading of cells  regulation of endothelial cell differentiation  negative regulation of fatty acid biosynthetic process  protein dimerization activity  negative regulation of T cell receptor signaling pathway  leukocyte migration  negative regulation of lipid biosynthetic process  regulation of blood vessel remodeling  extracellular exosome  regulation of ERK1 and ERK2 cascade  tertiary granule membrane  negative regulation of platelet aggregation  cell-cell adhesion via plasma-membrane adhesion molecules  insulin catabolic process  regulation of homophilic cell adhesion  regulation of sprouting angiogenesis  protein tyrosine kinase binding  negative regulation of hepatocyte proliferation  positive regulation of vasculogenesis  
REACTOMEP13688 [protein]
REACTOME PathwaysR-HSA-6798695 [pathway]   
NDEx NetworkCEACAM1
Atlas of Cancer Signalling NetworkCEACAM1
Wikipedia pathwaysCEACAM1
Orthology - Evolution
OrthoDB634
GeneTree (enSembl)ENSG00000079385
Phylogenetic Trees/Animal Genes : TreeFamCEACAM1
HOVERGENP13688
HOGENOMP13688
Homologs : HomoloGeneCEACAM1
Homology/Alignments : Family Browser (UCSC)CEACAM1
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerCEACAM1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)CEACAM1
dbVarCEACAM1
ClinVarCEACAM1
1000_GenomesCEACAM1 
Exome Variant ServerCEACAM1
ExAC (Exome Aggregation Consortium)ENSG00000079385
GNOMAD BrowserENSG00000079385
Genetic variants : HAPMAP634
Genomic Variants (DGV)CEACAM1 [DGVbeta]
DECIPHERCEACAM1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisCEACAM1 
Mutations
ICGC Data PortalCEACAM1 
TCGA Data PortalCEACAM1 
Broad Tumor PortalCEACAM1
OASIS PortalCEACAM1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICCEACAM1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDCEACAM1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch CEACAM1
DgiDB (Drug Gene Interaction Database)CEACAM1
DoCM (Curated mutations)CEACAM1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)CEACAM1 (select a term)
intoGenCEACAM1
NCG5 (London)CEACAM1
Cancer3DCEACAM1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM109770   
Orphanet
MedgenCEACAM1
Genetic Testing Registry CEACAM1
NextProtP13688 [Medical]
TSGene634
GENETestsCEACAM1
Target ValidationCEACAM1
Huge Navigator CEACAM1 [HugePedia]
snp3D : Map Gene to Disease634
BioCentury BCIQCEACAM1
ClinGenCEACAM1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD634
Chemical/Pharm GKB GenePA26358
Clinical trialCEACAM1
Miscellaneous
canSAR (ICR)CEACAM1 (select the gene name)
Probes
Litterature
PubMed199 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineCEACAM1
EVEXCEACAM1
GoPubMedCEACAM1
iHOPCEACAM1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 12 16:18:43 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.